S-adenosyl methionine (SAMe) for depression in adults

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 10, 2016, Pages

  Galizia, Ilaria ^a,b   Oldani, Lucio ^c   Macritchie, Karine ^a   Amari, Erica ^d   Dougall, Dominic ^e   Jones, Tessa N ^f   Lam, Raymond W ^d   Massei, Guido Jacopo ^g,h   Yatham, Lakshmi N ^d   Young, Allan H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BARI   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e EAST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^f CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF PISA   (Italy)

^h Versilia Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; IMIPRAMINE; PLACEBO; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; COMPARATIVE EFFECTIVENESS; DECREASED APPETITE; DEPRESSION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FLATULENCE; GRANDIOSE DELUSION; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERKINESIA; HYPOMANIA; INSOMNIA; IRRITABILITY; LOGORRHEA; MANIA; MONOTHERAPY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SIDE EFFECT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYSTEMATIC REVIEW; WEIGHT REDUCTION; AGED; META ANALYSIS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSION; HUMANS; IMIPRAMINE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; S-ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITORS;

EID: 84990950545     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011286.pub2     Document Type: Review

References (140)

1. Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry 1988;145(9):1110-14.
2. Potkin SG, Bell K, Plon L, Bunney WE Jr. Rapid antidepressant response with SAMe. A double-study. Alabama Journal of Medical Sciences 1988;25(3):313-6.
3. Bell KM, Carreon D, Plon L, Bunney We Jr, Potkin SG. Oral S-adenosylmethionine in the treatment of depression: a double-blind comparison with desipramine. Study report. BioResearch File 1990:53-4.
4. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica 1994;154(Suppl 1):15-8.
5. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular s-adenosyl-l-methionine 1, 4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition 2002;76(5):1172-6.
6. Delle Chiaie R, Pancheri P, Scapicchio P. Mc3: multicentre, controlled efficacy and safety trial of oral S-adenosyl-methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S230.
7. Delle Chiaie R, Pancheri P, Scapicchio P. Multicentre, controlled efficacy and safety trial of S-adenosyl-methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):230.
8. Delle Chiaie R, Pancheri P, Scapicchio P. S-adenosyl-methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA. 2002.
9. Delle Chiaie R, Pancheri R, Scapicchio P. S-adenosyl-methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10, New Orleans. 2000:NR499.
10. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular s-adenosyl-l-methionine 1, 4-butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition 2002;76(5):1172-6.
11. Delle Chiaie R, Pancheri P, Scapicchio P. Mc4: multicentre, controlled efficacy and safety trial of intramuscular S-adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S230.
12. Delle Chiaie R, Pancheri P, Scapicchio P. S-adenosyl-methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10, New Orleans. 2001:NR499.
13. Delle Chiaie R, Pancheri P, Scapicchio P. S-adenosyl-methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA. 2002.
14. Pancheri P, Scapicchio P, Delle Chiaie R. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1, 4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology 2002;5(4):287-94.
15. De Vanna M, Rigamonti R. Oral S-adenosyl-l-methionine in depression. Current Therapeutic Research, Clinical and Experimental 1992;52(3):478-85.
16. Kagan BL, Sultzer L, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry 1990;147(5):591-5.
17. Fava M. A double-blind, placebo-controlled study of the alternative therapy S-adenosyl-l-methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452]
18. Gerbarg PL, Muskin PR, Bottiglieri T, Brown RP. Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry 2014;75(11):e1328.
19. Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Fava M. Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry 2014;75(11):e1328-9.
20. Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Fava M, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-l-methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry 2014;75(4):370-6.
21. Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon D. S-adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders 2014;164:76-81.
22. Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI, et al. Is S-adenosyl methionine (SAMe) for depression only effective in males? A re-analysis of data from a randomized controlled trial. Pharmacopsychiatry 2015;48(4-5):141-4.
23. Mischoulon D, Alpert JE, Arning E, Bottiglieri T, Fava M, Papakostas GI. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry 2012;73(6):843-8.
24. Papakostas GI. S-Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment-resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847]
25. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. American Journal of Psychiatry 2010;167(8):942-8.
26. Agnoli A, Fazio C, Andreoli V. Neuropsychiatric disorders and transmethylations: therapeutic effects of S adenosyl L methionine [Disturbi neuropsichiatrici e transmetilazioni: effetti terapeutici della S adenosil l metionina]. Clinica Terapeutica 1975;75(6):567-79.
27. Agnoli A, Andreoli V, Casacchia M, Cerbo R. Effect of S-adenosyl-l-methionine (SAMe) upon depressive symptoms. Journal of Psychiatric Research 1976;13(1):43-54.
28. Agnoli A, Andreoli VM, Casacchia M, Maffei F, Fazio C. Results and possible developments of the clinical use of S-adenosyl-L-methionine (SAMe) in psychiatry. Monographien aus dem Gesamtgebiete der Psychiatrie 1978;18:170-82.
29. Alvarez E, Udina C, Guillamat R. Double blind study on the antidepressant activity of sulfoadenosyl-L-methionine (SAMe): clinical and biological factors [Estudio doble ciego sobre la efectividad antidepresiva del SAMe; factores clínicos y biológicos]. Revista del Departamento de Psiquiatría de la Facultad de Medicina de Barcelona 1984;11(4):275-88.
30. Bambling M, Parham SC, Coulson S, Vitetta L. S-adenosylmethionine (SAMe) and magnesium orotate as adjunctives to SSRIs in sub-optimal treatment response of depression in adults: a pilot study. Advances in Integrative Medicine 2015;2(1):56-62.
31. Barberi A, Pusateri C. The clinical effects of S-adenosyl-L-methionine (SAMe) in cases of depression [Sugli effetti clinici della S-adenosil-L-metionina (SAMe) nelle sindromi depressive]. Minerva Psichiatrica 1978;19(4):235-43.
32. Berlanga C, Ortega Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Research 1992;44(3):257-62.
33. Blasi Ras R. Comparative study of sulfoadenosyl-l-methionine and amoxapine in depression [Estudio comparativo sulfoadenosil-l-metionina con amoxapina en la patologia depresiva]. Psiquis, Revista de Psiquiatria, Psicologia y Psicosomatica 1985;6(4):35-44.
34. Bottiglieri T, Carney MWP, Edeh J, Laundy M, Martin R, Reynolds EH, et al. A biochemical study of depressed patients receiving S-adenosyl-L-methionine (SAM). Biological Methylation and Drug Design. Experimental Biology and Medicine 1986;12:327-38.
35. Bottiglieri T, Godfrey P, Flynn T, Carney MWP, Toone BK, Reynolds EH. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. Journal of Neurology, Neurosurgery, and Psychiatry 1990;53(12):1096-8.
36. Calandra C, Roxas M, Rapisarda V. The antidepressant action of SAMe compared with that of chloripramine and an interpretation of its mechanism [Azione antidepressiva della SAMe a paragone della clorimipramina. Ipotesi interpretative del meccanismo d'azione]. Minerva Psichiatrica 1979;20(2):147-52.
37. Carney MW, Edeh J, Bottiglieri T, Reynolds EM, Toone BK. Affective illness and S adenosylmethionine: a preliminary report. Clinical Neuropharmacology 1986;9(4):379-85.
38. De Leo D. S-adenosylmethionine as an antidepressant: a double-blind trial versus placebo. Current Therapeutic Research, Clinical and Experimental 1987;41(6):865-70.
39. Delle Chiaie R, Boissard G. Meta-analysis of two European multicenter controlled trials with ademetionine (SAMe) in major depression. 6th World Congress of Biological Psychiatry; 1997 22-27 Jun; Nice, France. 1997.
40. Delle Chiaie R, Pancheri P. Combined analysis of two controlled, multicentric, double-blind studies to assess efficacy and safety of sulfo-adenosyl-methionine (SAMe) vs. placebo (MC1) and SAMe vs. clomipramine (MC2) in the treatment of major depression [Analisi combinata di due studi controllati, multicentrici, in doppio cieco per la valutazione di efficacia e tollerabilita' di SAMe vs. placebo (MC1) e di SAMe vs. clomipramina (MC2) nel trattamento della depressione maggiore]. Giornale Italiano di Psicopatologia 1999;5:1-16.
41. Del Vecchio M, Iorio G, Cocurullo M, Vacca L, Amati A. Has SAMe (Ado Met) and antidepressant effect: a preliminary trial versus chlorimipramine. Rivista Sperimentale di Freniatria 1978;102:344-58.
42. Di Pierro F, Settembre R. Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression. International Journal of General Medicine 2015;8:73-8.
43. Fava M, Rosenbaum JF, Birnbaum R, Kelly K, Otto MW, MacLaughlin R. The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatrica Scandinavica 1992;86(1):42-5.
44. Janicak PG, Lipinski J, Davis JM, Altman E, Sharma RP. Parenteral S-adenosylmethionine (SAMe) in depression; literature review and preliminary data. Psychopharmacology Bulletin 1989;25(2):238-42.
45. Janicak PG, Lipinski J, Davis JM, Comaty JE, Waternaux C, Cohen B, et al. S-adenosylmethionine in depression. A literature review and preliminary report. Alabama Journal of Medical Sciences 1988;25(3):306-13.
46. Kufferle B, Grunberger J. Early clinical double-blind study with S-adenosyl-L-methionine: a new potential antidepressant. Advances in Biochemical Psychopharmacology 1982;32:175-80.
47. Lanaia F, Savoca G, Zappala E, Magro E, Calandra A. SAMe in depressive syndromes [La SAMe nelle sindromi depressive]. Igiene Mentale 1977;2:397-406.
48. Mantero M, Pastorino P. Depressive syndromes, skin disease and transmethylations. Therapeutic effects of S adenosyl L methionine [Sindromi depressive, malattie cutanee e transmetilazioni. Effetti terapeutici della S adenosil L metionina]. Gazzetta Medica Italiana 1976;135(12):707-16.
49. Muscettola G, Galzenati M, Balbi A. SAMe versus placebo: a double blind comparison in major depressive disorders. Advances in Biochemical Psychopharmacology 1982;32:151-6.
50. Rabassini A, Russo G. Effects of the association of maprotiline + SAMe in depressive syndromes [Effetti dell'associazione maprotilina + SAMe nelle sindromi depressive]. Psichiatria Generale e Dell'eta' Evolutiva 1979;3:305-23.
51. Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Grazie C. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychotherapy and Psychosomatics 1993;59(1):34-40.
52. Salmaggi P, Bressa GM, Niccia G, Coniglio M, La Greca P, Le Grazie C. Oral S-adenosylmethionine (SAMe) in the treatment of menopausal depressive disorder (MDD): a double-blind placebo controlled trial. European Journal of Clinical Investigation 1991;21(2 pt 2):58.
53. Sarris J, Stough C, Bousman C, Murphy J, Savage K, Smith DJ, et al. An adjunctive antidepressant nutraceutical combination in treating major depression: study protocol, and clinical considerations. Advances in Integrative Medicine 2015;2(1):49-55.
54. Scarzella R, Appiotti A. A double-blind clinical comparison of SAMe vs clomipramine in depressive disorders [Confronto clinico in doppio cieco della SAMe versus clorimipramina nelle sindromi depressive]. Rivista Sperimentale di Freniatria 1978;102:359-65.
55. Schifano F, Garofoli F. Dothiepin vs S-adenosylmethionine (SAMe) for the treatment of major depression in weaned alcoholics: a pilot study. European Neuropsychopharmacology 1993;3(3):330.
56. Thomas CS, Bottiglieri T, Edeh J, Carney MW, Reynolds EH, Toone BK. The influence of S-adenosylmethionine (SAM) on prolactin in depressed patients. International Clinical Psychopharmacology 1987;2(2):97-102.
57. Quiros G. Assessment of a new drug for depression: S-adenosyl-L-methionine [Valoracion de un nuevo farmaco en el tratamiento de las depresiones: la S-Adenosyl-L-Metionina]. Psicopatologia 1982;2(3):265-74.
58. Sarris J. Nutraceuticals as monotherapy treatments in major depressive disorder: a double-blind, randomised, placebo-controlled trial, 2013. www.anzctr.org.au/ACTRN12613001299796.aspx (accessed 3 August 2016). [www.anzctr.org.au/ACTRN12613001299796.aspx]
59. Sarris J, Murphy J. The efficacy of S-adenosyl methionine (SAMe) and a combination nutraceutical as monotherapy treatments in major depressive disorder: a double-blind, randomised, placebo-controlled trial. www.anzctr.org.au/ACTRN12613001299796.aspx (accessed 3 August 2016).
60. Sarris J. The efficacy of S-adenosylmethionine (SAMe) and a combination nutraceutical as adjunctive treatments in depression: a double-blind, randomized, placebo-controlled trial, 2013. www.anzctr.org.au/ACTRN12613001300763.aspx (accessed 3 August 2016). [www.anzctr.org.au/ACTRN12613001300763.aspx]
61. MSI Methylation Sciences, Inc A double-blind, placebo-controlled, randomized add-on study of MSI-195 (Methylation Sciences Inc. S-adenosyl-L-methionine, SAMe) for patients with major depressive disorder (MDD) who have had an inadequate response to current antidepressant therapy, 2013. clinicaltrials.gov/show/NCT01912196 (accessed 3 August 2016). [clinicaltrials.gov/show/NCT01912196]
62. Alderson P, Green S, Higgins JPT. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. 4.2.2. Chichester, UK: Wiley & Sons, Ltd, 2004.
63. Algeri S, Catto E, Curcio M, Ponzi F, Stamentinoli G. Changes in rat brain noradrenaline and serotonin after administration of S-adenosylmethionine. In: Zappia V, Usdin E, Salvatore F editor(s). Biochemical and Pharmacological Roles of Adenosylmethionine and the Central Nervous System. New York: Permagon Press, 1979:81-7.
64. Altman DG, Bland JM. Statistics notes: presentation of numerical data. BMJ 1996;312:572.
65. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
66. Alvarez E, Udina C, Guillamat R. Shortening of latency period in depressed patients treated with SAMe and other antidepressant drugs. Cell Biology Reviews 1987;S1:103-10.
67. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III). Washington DC: American Psychiatric Association, 1980.
68. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington DC: American Psychiatric Association, 1994.
69. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 2000.
70. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd edition. 2010.
71. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007954]
72. Bell KM, Potkin SG, Carreon L, Plot L, Bunney W. Oral S-adenosylmethionine in the treatment of depression: a double-blind, randomized comparison with desipramine. American Journal Psychiatry (submitted).
73. Bell K, Plon L, Nabel M. A controlled clinical trial of S-adenosylmethionine treatment of depression. Annual Review of Cell and Developmental Biology 1987;S1:111-20.
74. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Canadian Journal of Psychiatry 2007;52:46-54.
75. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
76. Royal Pharmaceutical Society of Great Britain, British Medical Association. British National Formulary. London: British Medical Association, September 2016.
77. Bottiglieri T. S-adenosyl-L-methionine (SAMe): from the bench to the bedside - molecular basis of a pleiotrophic molecule. American Journal of Clinical Nutrition 2002;78:1151S-7S.
78. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurologica Scandinavica. Supplementum 1994;154:7-14.
79. Byford S, Barrett B, Despiégel N, Wade A. Impact of treatment success on health service use and cost in depression: longitudinal database analysis. Pharmacoeconomics 2011;29(2):157-70. [DOI: 10.2165/11537360-000000000-00000]
80. Cantoni GL. The nature of the active methyl donor formed enzymatically from L-methionine and adenosine triphosphate. Journal of the American Chemical Society 1952;74(11):2942-3.
81. Carney MW, Chary TK, Bottiglieri T, Reynolds EH. The switch mechanism and the bipolar/unipolar dichotomy. British Journal of Psychiatry 1989;154:48-51.
82. Carpenter DJ. St. John's wort and S-adenosyl methionine as "natural" alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit?. Alternative Medicine Review 2011;16(1):17-39.
83. Chavez M. SAMe: S-Adenosylmethionine. American Journal of Health-System Pharmacy 2000;57(2):119-23.
84. Craig D, Rice S. NHS Economic Evaluation Database Handbook. York, UK: Centre for Reviews and Dissemination, University of York, 2007.
85. Craig Nelson J. S-Adenosyl Methionine (SAMe) augmentation in major depressive disorder. American Journal of Psychiatry 2010;167:889-91. [10.1176/appi.ajp.2010.10040627]
86. Curcio M, Catto E, Stramentinoli G, Algeri S. Effect of S-adenosyl-L-methionine on serotonin metabolism in rat brain. Progress in Neuro-Psychopharmacology 1978;2(1):65-71.
87. Davidson JR. Major depressive disorder treatment guidelines in America and Europe. Journal of Clinical Psychiatry 2010;71 Suppl E1:e04. [DOI: 10.4088/JCP.9058se1c.04gry]
88. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1, 4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition 2002;76(5) :1172S-6S.
89. DerSimonian R, Laird N. Meta-analysis in Clinical Trials. Controlled Clinical Trials 1986;7:177-88.
90. Di Padova C, Giudici A, Boissard G. Ademetionine and depression. IV Workshop on methionine metabolism: molecular mechanisms and clinical implications; 2000 Feb 20-24; Granada, Spain. 2000:295-9.
91. Di Rocco A, Rogers JD, Brown R, Werner P, Bottiglieri T. S-Adenosyl methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Movement Disorders 2000;15 (6):1225-9.
92. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
93. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
94. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. Journal of Clinical Psychiatry 1983;44(8, Pt2):8-11.
95. Fazio C, Andreoli V, Agnoli A, Casacchia M, Cerbo R. Therapy of schizophrenic and depressive disorders with S-adenosylmethionine. Clinical Pharmacology & Therapeutics 1974;2:1015.
96. Fleisch SB, Travis MJ, Ryan ND. Discrepancy in response and remission rates for SAMe-treated patients in a double-blind, randomized clinical trial [comment]. American Journal of Psychiatry 2010;167(12):1533.
97. Furukawa TA, Barbui C, Cipriani A, Brambillac P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
98. Goldberg D, Fawcett J. The importance of anxiety in both major depression and bipolar disorder. Depression and Anxiety 2012;29(6):471-8.
99. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. Journal of Clinical Psychiatry 2003;64(12):1465-75.
100. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
101. Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 2004;24(11):1501-7.
102. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960;23:56-62.
103. Hardy M, Coulter I, Morton SC, Favreau J, Venuturupalli S, Chiappelli F, et al. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evidence Report/Technology Assessment Number 64. Rockville, MD: Agency for Healthcare Research and Quality October 2002.
104. Henkel V, Mergi R, Allgaier AK, Kohnen R, Möller HJ, Hegeri U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Research 2006;141:89-101.
105. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
106. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. [DOI: http://dx.doi.org/10.1136/bmj.d5928]
107. Kessler RC. The costs of depression. Psychiatric Clinics of North America 2012;35(1):1-14. [DOI: 10.1016/j.psc.2011.11.005]
108. McCrone P, Dhanasiri S, Pate A, Knapp M, Lawton-Smith S. Paying the Price. The Cost of Mental Health Care in England to 2026. London: The King's Fund, 2008.
109. Kresge N, Tabor H, Simoni RD, Hill RL. An escape from Italy, the discovery of S-adenosylmethionine, and the biosynthesis of creatine by Giulio L. Cantoni. Journal of Biological Chemistry 2005;280:e35.
110. Lipinski JF, Cohen BM, Frankenburg F, Tohen M, Waternaux C, Altesman R, Jones B. Open trial of S-adenosylmethionine for treatment of depression. American Journal of Psychiatry 1984;141:448-50.
111. Macher JR. A double-blind, placebo-controlled trial of intravenous ademetionine (SAMe) in the treatment of major depression (DSM III-R). International Clinical Psychopharmacology (in press).
112. Macher JP. A double blind placebo controlled trial of intravenous ademetionine (SAMe) in the treatment of major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2000;24(2):207-25.
113. Mischoulon D, Fava M. Role of S-adenosyl L-methionine in the treatment of depression: a review of the evidence. American Journal of Clinical Nutrition 2002;76:1158S-61S.
114. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
115. Morelli V, Zoorob RJ. Alternative therapies: Part I. Depression, diabetes, obesity. American Family Physician 2000;62(5):1051-60.
116. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349(9063):1436-42.
117. Nemeroff CB. Prevalence and management of treatment-resistant depression. Journal of Clinical Psychiatry 2007;68 Suppl 8:17-25.
118. National Institute for Health and Care Excellence. Depression in adults. The treatment and management of depression in adults. NICE clinical guideline 90 October 2009.
119. Otero-Losado ME, Rubio MC. Acute effects of S-adenosylmethionine on catecholaminergic central function. European Journal of Pharmacology 1989;163:353-6.
120. Otero-Losado ME, Rubio MC. Acute changes in 5HT metabolism after S-adenosylmethionine administration. General Pharmacology 1989;20:403-6.
121. Pancheri P, Racagni G, Delle Chiaie RD. Recent experimental and clinical findings of the efficacy and safety of adementionine (SAMe) in the pharmacological treatment of depression. Giornale Italiano di Psicopatologia 1997;3:1-23.
122. Papakostas GI, Alpert JE, Fava M. S-adenosyl methionine in the treatment of depression: a comprehensive review of the literature. Current Psychiatry Reports 2003;5:460-6.
123. Papakostas GI. 'Discrepancy in response and remission rates for SAMe-treated patients in a double-blind, randomized clinical trial': reply to Fleisch et al [letter]. American Journal of Psychiatry 2010;167(12):1533.
124. Pinzello A, Andreoli V. SAMe-dependent transmethylation in the depressive syndromes: evaluation of the therapeutic effect of S-adenosylmethionine using Hamilton Rating Scale [Le transmetilazioni SAM-dipendenti nelle sindromi depressive. Valutazione dell'effetto terapeutico della S-adenosilmetionina con la scala di Hamilton]. Quaderno Terapeutico Sperimentale; Supplemento Biochimica e Biol Sperimentale 1972;10(2):3-11.
125. Posternak MA, Zimmermann M. Short-term spontaneous improvement rates in depressed outpatients. Journal of Nervous and Mental Disease 2000;188(12):799-804.
126. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD002235.pub2]
127. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
128. Rothwell PM. External validity of randomised controlled trials: to whom do the results apply?. Lancet 2005;365:82-93.
129. Sackett DL, Deeks JJ, Altman DG. Down with odds ratios!. Evidence Based Medicine 1996;1:164-6.
130. Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. Journal of Psychiatric Research 2010;44:32-41.
131. Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI, et al. Is S-adenosyl methionine (SAMe) for depression only effective in males? A re-analysis of data from a randomized controlled trial. Pharmacopsychiatry 2015;48(4-5):141-4.
132. Shippy RA, Mendez D, Jones K, Cergnul I, Karpiak SE. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. BMC Psychiatry 2004;4:38.
133. Sinclair JC, Bracken MB. Clinically useful measures of effect in binary analyses of randomized trials. Journal of Clinical Epidemiology 1994;47:881-9.
134. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. Journal of Mental Health Policy and Economics 2006;9(2):87-98.
135. Stramentinoli G, Gualano M, Galli-Kienzle M. Intestinal absorption of S-adenosyl-L-methionine. Journal of Pharmacology and Experimental Therapeutics 1979;209:323-6.
136. Sugden C. One-carbon metabolism in psychiatric illness. Nutrition Research Reviews 2006;19:117-36.
137. World Health Organization. Mental disorders: glossary and guide to their classification in accordance with the ninth revision of the International Classification of Diseases. Geneva: WHO, 1978.
138. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Geneva: World Health Organization, 1992.
139. Williams AL, Girard C, Jui D, Sabina A, Katz Dl. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clinical and Investigative Medicine 2005;28:132-9.
140. Galizia I, Oldani L, Macritchie K, Amari E, Dougall D, Jones TN, et al. S-adenosyl methionine (SAM-e) for depression in adults. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD011286]